Sequence LifeScience, Inc Receives IRB Approval for a Novel Matched Controls Clinical Trial Targeting Diabetic Foot Ulcers (DFUs)
FOR IMMEDIATE RELASE Sequence LifeScience, Inc Receives IRB Approval for a Novel Matched Controls Clinical Trial Targeting Diabetic Foot Ulcers (DFUs) Groundbreaking study aims to improve healing outcomes and reduce complications for patients with chronic wounds. The study will also reduce the number of patients being randomized into control groups by utilizing historic controls data … Read more